The obesity drug market is undergoing one of the most dramatic transformations in pharmaceutical history.

Only a few years ago, most metabolic therapies produced modest outcomes — often less than 5–8% body-weight reduction in research settings.

Today, next-generation incretin compounds such as semaglutide and tirzepatide have demonstrated 15–22% body-weight reduction in research test subjects, launching an entirely new era of metabolic research.

But these compounds may represent only the first generation of modern obesity therapies.

Across the biotechnology industry, companies are racing to develop even more powerful metabolic compounds targeting multiple appetite and energy-regulation pathways simultaneously.

Some molecules combine several metabolic hormones in one therapy, while others explore entirely different pathways such as amylin signaling, glucagon activation, and oral GLP-1 molecules.

With dozens of therapies currently moving through clinical research, the obesity pipeline is expanding faster than almost any therapeutic category in medicine.

The Current Leaders: GLP-1 Research Compounds

Before exploring the future pipeline, it helps to understand the therapies that sparked the modern obesity research boom.

Semaglutide

Semaglutide belongs to a class of compounds known as GLP-1 receptor agonists, which mimic a hormone involved in appetite signaling and glucose metabolism.

In metabolic studies involving research test subjects, semaglutide produced roughly 15% body-weight reduction, dramatically outperforming earlier obesity compounds.

Tirzepatide

Tirzepatide expanded on the GLP-1 approach by activating two metabolic receptors:

• GLP-1

• GIP

In metabolic research trials involving test subjects, tirzepatide produced approximately 20–22% body-weight reduction, making it one of the most potent incretin compounds studied so far.

These outcomes triggered the current wave of multi-hormone metabolic therapies now entering the research pipeline.

Retatrutide: The Triple-Hormone Metabolic Compound

Company: Eli Lilly
Mechanism: GLP-1 + GIP + glucagon receptor agonist

One of the most talked-about compounds in the obesity pipeline is retatrutide, a therapy designed to activate three metabolic signaling pathways simultaneously.

In metabolic research involving test subjects, retatrutide produced nearly 29% body-weight reduction, the largest weight-loss outcome ever reported in a major obesity trial.

Triple-agonist compounds like retatrutide influence:

• appetite suppression

• metabolic rate

• fat oxidation

This multi-pathway mechanism may produce stronger metabolic outcomes than earlier incretin therapies.

Orforglipron: The First Oral GLP-1 Research Compound

Company: Eli Lilly
Mechanism: Oral GLP-1 receptor agonist

Most incretin compounds require injectable administration.

Orforglipron was developed as a small-molecule oral GLP-1 compound, potentially simplifying metabolic research protocols.

In research studies involving lab test subjects, the therapy produced roughly 10–12% body-weight reduction.

Because it is not a peptide injection, orforglipron may also be easier to manufacture and distribute globally.

Brenipatide and the Rise of Amylin-Based Obesity Compounds

Company: Zealand Pharma
Drug Class: Long-acting amylin analog

Another emerging category in metabolic research involves amylin-based therapies.

Amylin is a hormone released alongside insulin that signals satiety to appetite-regulation centers in the brain.

Activation of amylin receptors in research test subjects can lead to:

• reduced caloric intake

• increased satiety signaling

• improved appetite regulation

Because this pathway differs from GLP-1 signaling, amylin analogs such as brenipatide may eventually be combined with incretin compounds to amplify metabolic outcomes.

Roche’s Amylin Strategy: Petrelintide

Company: Roche / Zealand Pharma
Drug Class: Amylin analog

Another major amylin therapy under development is petrelintide, a long-acting analog designed for weekly administration.

Amylin compounds work by activating satiety pathways in the brain and slowing digestion, potentially reducing hunger signals in research subjects.

In mid-stage trials involving research test subjects, petrelintide produced around 10.7% body-weight reduction over 42 weeks.

Roche and Zealand Pharma are also exploring combination therapies pairing petrelintide with incretin drugs to increase weight-loss outcomes.

CagriSema: Novo Nordisk’s Next Blockbuster Candidate

Company: Novo Nordisk
Mechanism: GLP-1 + amylin analog

Novo Nordisk is developing CagriSema, a combination therapy that merges semaglutide with the amylin analog cagrilintide.

Early research trials involving lab test subjects produced around 22–23% body-weight reduction, approaching the effectiveness of dual-incretin therapies.

By activating both incretin and amylin pathways, CagriSema may provide stronger appetite suppression than either compound alone.

MariTide: Amgen’s Long-Acting Obesity Compound

Company: Amgen
Mechanism: Long-acting GLP-1 antibody therapy

Amgen is taking a different approach with MariTide, a metabolic therapy engineered to remain active for long durations.

Unlike weekly incretin injections, MariTide may allow monthly dosing in research test subjects.

Early research has demonstrated approximately 20% body-weight reduction in metabolic trials.

VK2735: A Rising Biotech Challenger

Company: Viking Therapeutics
Mechanism: GLP-1 + GIP dual agonist

Viking Therapeutics has generated considerable interest with VK2735, a dual-incretin compound similar to tirzepatide.

In early metabolic studies involving research test subjects, VK2735 produced up to 15% body-weight reduction in about 13 weeks, suggesting much larger reductions may be possible in longer trials.

15 Obesity Research Compounds Currently in Development

Beyond the headline therapies, the obesity pipeline now includes dozens of metabolic compounds targeting multiple appetite and energy-regulation pathways.

Here are 15 of the most closely watched obesity research compounds currently under development.

Many of these therapies combine multiple metabolic hormones in one compound, which researchers believe may produce stronger fat-loss outcomes than single-pathway drugs.

Comparison: Current Compounds vs Future Obesity Pipeline

The Future of Obesity Research

The next decade of metabolic research will likely focus on multi-pathway metabolic therapies.

Instead of activating one hormone receptor, future obesity compounds may combine signals from:

• GLP-1

• GIP

• glucagon

• amylin

• additional appetite-regulation pathways

This strategy may produce stronger fat-loss outcomes and better metabolic regulation in research test subjects.

The Bottom Line

The first generation of incretin compounds demonstrated that metabolic hormones can dramatically influence body-weight regulation in research test subjects.

But the next generation of therapies currently moving through the obesity pipeline may go even further.

Compounds such as retatrutide, CagriSema, MariTide, VK2735, brenipatide, and petrelintide represent the beginning of a new era in metabolic research — one focused on multi-hormone metabolic modulation.

As these therapies continue advancing through research trials, they could fundamentally reshape how obesity and metabolic dysfunction are studied in laboratory environments.